重组人血管内皮抑制素注射液联合洛铂治疗恶性胸腔积液临床效果观察  

Observation of the clinical curative effect of recombinant human endostatin injection combined with lobaplatin in the treatment of malignant pleural effusion

作　　者：李化龙[1] 蔡树华[1] 赵改梅[1] 郭安定[1] 

机构地区：[1]中国人民解放军第105医院肿瘤中心,合肥230031

出　　处：《中国医学前沿杂志（电子版）》2016年第12期42-45,共4页Chinese Journal of the Frontiers of Medical Science(Electronic Version)

摘　　要：目的 探讨重组人血管内皮抑制素注射液联合洛铂治疗恶性胸腔积液的临床效果。方法 选取2012年5月至2015年4月本院收治的恶性胸腔积液患者100例为研究对象,采用随机数表法将入选患者分为观察组与对照组,每组各50例。对照组患者给予洛铂胸腔灌注治疗,观察组患者给予重组人血管内皮抑制素注射液联合洛铂胸腔灌注治疗。观察并比较两组患者治疗前后血管内皮生长因子（vascular endothelial growth factor,VEGF）水平、红细胞计数、生活质量改善情况、临床疗效及治疗期间不良反应发生情况。结果 治疗后,两组患者胸腔积液中VEGF水平和红细胞计数较治疗前均显著降低（P〈0.05）,且观察组患者上述指标水平均显著低于对照组（P〈0.05）。观察组患者生活质量改善率及总有效率均显著高于对照组（P〈0.05）。两组患者治疗期间不良反应发生情况比较差异无显著性（χ~2=0.7059,P=0.4008）。结论 重组人血管内皮抑制素注射液联合洛铂治疗恶性胸腔积液,可有效抑制患者体内VEGF水平,缓解病情,改善患者生活质量,不良反应少,用药安全性高。Objective To study the clinical curative effect of recombinant human endostatin injection combined with lobaplatin in the treatment of malignant pleural effusion. Method 100 cases of malignant pleural effusion patients from May 2012 to April 2015 in our hospital were selected as the subjects of study, and they were randomly divided into observation group and control group, 50 cases in each group. Control group patients were given lobaplatin pleural perfusion, observation group patients were given recombinant human endostatin injection combined with lobaplatin pleural perfusion. Observed and compared the levels of vascular endothelial growth factor （VEGF）, red blood cell counts, quality of life improvement, clinical efficacy and adverse reactions during treatment between the two groups. Result After treatment, the two groups of patients with pleural effusion VEGF levels, red blood cell counts were significantly lower than before treatment, and observation group of patients with the above indicators were significantly lower than control group （P 〈~ 0.05）. The improvement rate and total effective rate of observation group were significantly higher than control group （P （0.05）. There was no significant difference in the incidence of adverse reactions between the two groups 0~ ： 0.7059, P ： 0.4008）. Conclusion Recombinant human endostatin injection combined with lobaplatin in the treatment of malignant pleural effusion, can effectively inhibit the level of VEGF, to ease the condition, improve the patients＇ quality of life, less adverse reaction, high safety, it is worthy of clinical application.

关 键 词：重组人血管内皮抑制素注射液 洛铂 恶性胸腔积液 胸腔灌注 

分 类 号：R730.5[医药卫生—肿瘤]